Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?
The optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared the safety and efficacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days (n=59) versus 2 mg/kg for 3 days (n=59), in a retrospective, cohort study. Results. Two-year rejection...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2010/957549 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566160179068928 |
|---|---|
| author | Karen L. Hardinger Rafia S. Rasu Rebecca Skelton Brent W. Miller Daniel C. Brennan |
| author_facet | Karen L. Hardinger Rafia S. Rasu Rebecca Skelton Brent W. Miller Daniel C. Brennan |
| author_sort | Karen L. Hardinger |
| collection | DOAJ |
| description | The optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared the safety and efficacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days (n=59) versus 2 mg/kg for 3 days (n=59), in a retrospective, cohort study. Results. Two-year rejection-free survival was 95% in each group (P=.983). Renal function and infection rates were similar. The incidence of leucopenia was similar, although the 2 mg/kg group was more likely to be thrombocytopenic on day 2 (4% versus 28%, P=.04). Length of stay tended to be longer for the 1.5 mg/kg group (6.0±3.7 versus 5.1±1.9 days P=.104). A cost savings of $920 per patient for rATG were seen in the 2 mg/kg group (P=.122). Conclusions. Shorter, more intense dosing of rATG is safe and effective. The 3-day dose strategy resulted in a clinically shorter length of stay and may result in cost savings. |
| format | Article |
| id | doaj-art-c951500c66d94cffa2203fe27377249d |
| institution | Kabale University |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-c951500c66d94cffa2203fe27377249d2025-02-03T01:04:57ZengWileyJournal of Transplantation2090-00072090-00152010-01-01201010.1155/2010/957549957549Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?Karen L. Hardinger0Rafia S. Rasu1Rebecca Skelton2Brent W. Miller3Daniel C. Brennan4Division of Pharmacy Practice and Administration, University of Missouri-Kansas City, Kansas City, MO 64108, USADivision of Pharmacy Practice and Administration, University of Missouri-Kansas City, Kansas City, MO 64108, USADepartment of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Avenue Campus Box 8126, St. Louis, MO 63110, USADepartment of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Avenue Campus Box 8126, St. Louis, MO 63110, USADepartment of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Avenue Campus Box 8126, St. Louis, MO 63110, USAThe optimal dose and duration of rabbit antithymocyte globulin (rATG) induction has not been defined. Methods. We compared the safety and efficacy of 2 dosing strategies, rATG 1.5 mg/kg for 4 days (n=59) versus 2 mg/kg for 3 days (n=59), in a retrospective, cohort study. Results. Two-year rejection-free survival was 95% in each group (P=.983). Renal function and infection rates were similar. The incidence of leucopenia was similar, although the 2 mg/kg group was more likely to be thrombocytopenic on day 2 (4% versus 28%, P=.04). Length of stay tended to be longer for the 1.5 mg/kg group (6.0±3.7 versus 5.1±1.9 days P=.104). A cost savings of $920 per patient for rATG were seen in the 2 mg/kg group (P=.122). Conclusions. Shorter, more intense dosing of rATG is safe and effective. The 3-day dose strategy resulted in a clinically shorter length of stay and may result in cost savings.http://dx.doi.org/10.1155/2010/957549 |
| spellingShingle | Karen L. Hardinger Rafia S. Rasu Rebecca Skelton Brent W. Miller Daniel C. Brennan Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days? Journal of Transplantation |
| title | Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days? |
| title_full | Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days? |
| title_fullStr | Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days? |
| title_full_unstemmed | Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days? |
| title_short | Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days? |
| title_sort | thymoglobulin induction dosing strategies in a low risk kidney transplant population three or four days |
| url | http://dx.doi.org/10.1155/2010/957549 |
| work_keys_str_mv | AT karenlhardinger thymoglobulininductiondosingstrategiesinalowriskkidneytransplantpopulationthreeorfourdays AT rafiasrasu thymoglobulininductiondosingstrategiesinalowriskkidneytransplantpopulationthreeorfourdays AT rebeccaskelton thymoglobulininductiondosingstrategiesinalowriskkidneytransplantpopulationthreeorfourdays AT brentwmiller thymoglobulininductiondosingstrategiesinalowriskkidneytransplantpopulationthreeorfourdays AT danielcbrennan thymoglobulininductiondosingstrategiesinalowriskkidneytransplantpopulationthreeorfourdays |